BeiGene
BGNE
#881
Rank
S$28.88 B
Marketcap
$263.10
Share price
1.71%
Change (1 day)
-0.19%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : S$3.05 B

According to BeiGene 's latest financial reports the company's total liabilities are S$3.05 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31S$2.99 B11.94%
2022-12-31S$2.67 B-17.43%
2021-12-31S$3.24 B41.57%
2020-12-31S$2.28 B168.53%
2019-12-31S$0.85 B26.15%
2018-12-31S$0.67 B39.47%
2017-12-31S$0.48 B532.76%
2016-12-31S$76.57 M27.42%
2015-12-31S$60.09 M63.29%
2014-12-31S$36.8 M-42.52%
2013-12-31S$64.02 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
S$15.83 M-99.48%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.76 B-75.08%๐Ÿ‡บ๐Ÿ‡ธ USA